6 results
Primary objectivesEfficacyThe primary efficacy objective is to determine, as a superiority assessment, whether treatment with saxagliptin compared with placebo when added to current background therapy will result in a reduction in the composite…
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
To investigate if subjects with an increased risk of developing spondyloarthritis have evidence of bone formation on [18F] Fluoride PET-CT.
The aim is to investigate the therapeutic effects of Secukinumab on bone formation in SpA patients by using [18F]Fluoride PET-CT imaging, and to investigate cellular and molecular pathology in bone formation.
The primary objectives of this study are:• To determine the safety and tolerability of EP-104IAR• To determine the pharmacokinetic (PK) profile of EP-104IARA secondary/exploratory objective is:• To evaluate the efficacy of EP-104IAR on eosinophilic…
The primary objective of this proof-of-concept study is to investigate the feasibility of whole body [18F]Fluoride PET-CT scans to detect axial and peripheral neew bone formation in PsA patients taht are at risk to develop clinically manifest PsA.…